Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maral Saadati

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Leukemia|January 23, 2024
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohortsJacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, et al.
The Lancet. Haematology|May 15, 2023
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trialHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Nature|October 16, 2015
Telomerase activation by genomic rearrangements in high-risk neuroblastomaMartin Peifer, Falk Hertwig, Frederik Roels, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Leukemia|January 23, 2024
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohortsJacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, et al.
The Lancet. Haematology|May 15, 2023
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trialHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Nature|October 16, 2015
Telomerase activation by genomic rearrangements in high-risk neuroblastomaMartin Peifer, Falk Hertwig, Frederik Roels, et al.
Pageof 4